H. Lundbeck Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Deborah Dunsire
Chief executive officer
kr.56.6m
Total compensation
CEO salary percentage | 17.5% |
CEO tenure | 3.9yrs |
CEO ownership | n/a |
Management average tenure | 3.5yrs |
Board average tenure | 1.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2022 | n/a | n/a | kr.1b |
Dec 31 2021 | kr.57m | kr.10m | kr.1b |
Sep 30 2021 | n/a | n/a | kr.2b |
Jun 30 2021 | n/a | n/a | kr.2b |
Mar 31 2021 | n/a | n/a | kr.2b |
Dec 31 2020 | kr.26m | kr.10m | kr.2b |
Sep 30 2020 | n/a | n/a | kr.904m |
Jun 30 2020 | n/a | n/a | kr.1b |
Mar 31 2020 | n/a | n/a | kr.2b |
Dec 31 2019 | kr.21m | kr.9m | kr.2b |
Sep 30 2019 | n/a | n/a | kr.3b |
Jun 30 2019 | n/a | n/a | kr.3b |
Mar 31 2019 | n/a | n/a | kr.4b |
Dec 31 2018 | kr.14m | kr.3m | kr.4b |
Compensation vs Market: Deborah's total compensation ($USD7.87M) is about average for companies of similar size in the US market ($USD7.79M).
Compensation vs Earnings: Deborah's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Deborah Dunsire (60 yo)
3.9yrs
Tenure
kr.56,600,000
Compensation
Dr. Deborah Dunsire, M.D. serves as Director at Syros Pharmaceuticals, Inc. since September 09, 2021. She serves as Chief Executive Officer and President at H. Lundbeck A/S since September 1, 2018 and serv...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President & CEO | 3.9yrs | kr.56.60m | no data | |
Executive VP of Commercial Operations & Chief Commercial Officer | 4.8yrs | kr.8.70m | 0% DKK 0 | |
Executive Vice President of Product Development & Supply | 3.6yrs | kr.9.00m | 0% DKK 0 | |
Executive Vice President of Research & Development | 3.6yrs | kr.8.40m | 0% DKK 0 | |
Senior Vice President Group Finance | no data | no data | no data | |
Senior VP & Head of Research | 1.3yrs | no data | no data | |
Chief Specialist & VP of Investor Relations | no data | no data | no data | |
Executive Vice President of People & Communication | 2.9yrs | no data | 0% DKK 0 | |
Senior Vice President of International Markets | no data | no data | no data | |
Executive Vice President of Corporate Strategy & Business Development | 3.4yrs | no data | no data | |
Senior VP & Head of Clinical Development | less than a year | no data | no data | |
Vice President of Clinical Research Neurology | no data | no data | no data |
3.5yrs
Average Tenure
59yo
Average Age
Experienced Management: HLUY.Y's management team is considered experienced (3.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | 5.6yrs | no data | no data | |
Independent Chairman | 9.6yrs | no data | 0% DKK 0 | |
Deputy Chairman | 7.6yrs | no data | 0.0021% DKK 102.5k | |
Independent Director | 4.4yrs | no data | no data | |
Director | 7.6yrs | no data | 0% DKK 0 | |
Independent Director | 1.4yrs | no data | no data | |
Independent Director | 1.4yrs | no data | no data | |
Employee Representative Director | less than a year | no data | no data | |
Employee Representative Director | less than a year | no data | no data | |
Employee Representative Director | less than a year | no data | no data | |
Employee Representative Director | less than a year | no data | no data |
1.4yrs
Average Tenure
60yo
Average Age
Experienced Board: HLUY.Y's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.